Strong Combined Revenue and Organic Growth
Total reported Q1 revenue $1.267B; organic revenue $747M and grew 13% as reported / 11% constant currency versus Q1 2025; orders outpaced sales.
Acquisition Performance Beat
Revenue from Biosciences and Diagnostic Solutions during owned period $520M, beating guidance by $40M; Biosciences: $230M (~7% estimated as‑reported growth); Diagnostic Solutions: $288M (~8% estimated as‑reported growth).
Adjusted EPS and Margin Outperformance
Adjusted EPS grew 20% year‑over‑year to $2.70, beating the high end of guidance by $0.35; adjusted gross margin 54.7% (~200 bps better than expected); adjusted operating margin 23.6% (~200 bps better than expected).
Raised Full‑Year Guidance
Organic constant currency revenue guidance raised to 6.5%–8% for 2026; total reported 2026 revenue now expected ~$6.405B–$6.455B; adjusted EPS guidance raised $0.10 to $14.40–$14.60 (10%–11% growth).
Synergy Progress and Targets on Track
On track to deliver $55M in cost synergies for 2026; targeting $50M in revenue synergies for 2026 with $35M expected contribution from acquired businesses; restructuring savings to start hitting P&L in Q3.
Commercial Execution and Early Revitalization (180‑day Plan)
Launched rapid 180‑day plan to increase forecast rigor, field activity and pricing discipline; increased call volumes and deal desk deployment; initial contract review in U.S. Diagnostics found ~700 out‑of‑compliance contracts (double‑digit million annual opportunity).
Product and Regulatory Milestones
BACTEC FXI blood culture system received CE marking (faster detection, 60-sample loading); FDA cleared BD Onclarity HPV self‑collection kit and assay; launched Microflow LC Chemistry Columns (up to 2x sensitivity) and omniDAWN detector—strengthening differentiation in bioseparations and light scattering.
Instrument Replacement and Service Upside
Identified ~22,000 instruments ripe for replacement (12,000 BACTEC; >50% >5 years old); service plan attachment initiatives expected to generate at least $20M incremental revenue over 5 years; accelerated BACTEC FXI U.S./EU launch by 3–5 months.